Skip to main
ONC

BeiGene Ltd (ONC) Stock Forecast & Price Target

BeiGene Ltd (ONC) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 38%
Buy 62%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BeOne Medicines is supported by a highly durable Brukinsa franchise, which generated about $1.25B in 2Q26 global sales, rose 31% year over year, and is tracking toward more than $5B in 2026 revenue, giving the company a dominant cash-generating core. The company also showed operating strength with 2Q26 total revenue of $1.7B, diluted EPS of $2.05, and $5.28B in cash and equivalents, while raising full-year guidance for revenue to $6.6B-$6.8B and operating income to $1.0B-$1.1B. Beyond Brukinsa, its more than 50 clinical-stage programs and multiple Phase 3 oncology readouts, including Tevimbra and sonrotoclax, create multiple paths for growth and de-risk the business over time.

Bears say

BeOne Medicines is viewed negatively because its investment case remains heavily dependent on Brukinsa, which accounted for 74% of total revenue in 2025, leaving the company exposed if growth slows or competitors gain share against AbbVie and AstraZeneca. The broader pipeline does not offset that concentration risk, since drug development is capital-intensive and uncertain, and the excerpt highlights that many programs fail in clinical development, face regulatory delays, or lack differentiated data needed to drive commercial success. Competitive pressure is also underscored by Sanofi’s CEA-targeted ADC setback in December 2023, showing how even promising oncology assets can fail to improve outcomes such as progression-free survival, which raises the risk of setbacks across BeOne’s more than 50 clinical trials.

BeiGene Ltd (ONC) has been analyzed by 13 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 62% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BeiGene Ltd (ONC) Forecast

Analysts have given BeiGene Ltd (ONC) a Buy based on their latest research and market trends.

According to 13 analysts, BeiGene Ltd (ONC) has a Buy consensus rating as of Oct 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $407.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $407.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BeiGene Ltd (ONC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.